ROSSANA RONCATO^1,2, JERRY POLESEL³, FEDERICA TOSI^4,5,*, ELENA PERUZZI^1,*, ERIKA BRUGUGNOLI⁶, CLAUDIA LAURIA PANTANO⁷, MARIA FURFARO⁸, FILIPPO DI GIROLAMO^9,10, ALESSANDRO NANI¹¹, ARIANNA PANI⁴, NOEMI MILAN¹, ELENA DE MATTIA¹, ANDREA SARTORE-BIANCHI^4,5, ERIKA CECCHIN¹

Oncology Research, Vol.32, No.9, pp. 1407-1422, 2024, DOI:10.32604/or.2024.049181 - 23 August 2024

Abstract Objectives: Treatment of metastatic colorectal cancer (mCRC) includes resection of liver metastases (LM), however, no validated biomarker identifies patients most likely to benefit from this procedure. This meta-analysis aimed to assess the impact of the most relevant molecular alterations in cancer-related genes of CRC (i.e., RAS, BRAF, SMAD4, PIK3CA) as prognostic markers of survival and disease recurrence in patients with mCRC surgically treated by LM resection. Methods: A systematic literature review was performed to identify studies reporting data regarding survival and/or recurrence in patients that underwent complete liver resection for CRC LM, stratified according to… More > Graphic Abstract

YUNG-SUNG YEH^1,2,3, HSIANG-LIN TSAI^4,5, YEN-CHENG CHEN^4,6, WEI-CHIH SU^4,6, PO-JUNG CHEN^4,6, TSUNG-KUN CHANG^4,6,7, CHING-CHUN LI⁴, CHING-WEN HUANG^4,5, JAW-YUAN WANG^{4,5,6,8,9,10,*}

Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659 - 05 January 2023

Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >